FI120397B - Uudet sulfonamidit - Google Patents

Uudet sulfonamidit Download PDF

Info

Publication number
FI120397B
FI120397B FI972628A FI972628A FI120397B FI 120397 B FI120397 B FI 120397B FI 972628 A FI972628 A FI 972628A FI 972628 A FI972628 A FI 972628A FI 120397 B FI120397 B FI 120397B
Authority
FI
Finland
Prior art keywords
methoxy
phenoxy
pyridin
pyrimidin
tetrazol
Prior art date
Application number
FI972628A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972628L (fi
FI972628A0 (fi
Inventor
Werner Neidhart
Henri Ramuz
Volker Breu
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Kaspar Burri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI972628L publication Critical patent/FI972628L/fi
Publication of FI972628A0 publication Critical patent/FI972628A0/fi
Application granted granted Critical
Publication of FI120397B publication Critical patent/FI120397B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
FI972628A 1994-12-20 1997-06-18 Uudet sulfonamidit FI120397B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH383794 1994-12-20
CH241995 1995-08-24
CH241995 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides
EP9504843 1995-12-08

Publications (3)

Publication Number Publication Date
FI972628L FI972628L (fi) 1997-06-18
FI972628A0 FI972628A0 (fi) 1997-06-18
FI120397B true FI120397B (fi) 2009-10-15

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972628A FI120397B (fi) 1994-12-20 1997-06-18 Uudet sulfonamidit

Country Status (25)

Country Link
US (1) US6004965A (Direct)
EP (1) EP0799209B1 (Direct)
JP (1) JP2989014B2 (Direct)
KR (1) KR100445085B1 (Direct)
CN (1) CN1098254C (Direct)
AT (1) ATE246681T1 (Direct)
AU (1) AU701767B2 (Direct)
BR (1) BR9510104A (Direct)
CA (1) CA2208018C (Direct)
CY (1) CY2495B1 (Direct)
CZ (1) CZ287916B6 (Direct)
DE (1) DE69531457T2 (Direct)
DK (1) DK0799209T3 (Direct)
ES (1) ES2203649T3 (Direct)
FI (1) FI120397B (Direct)
HU (1) HU228619B1 (Direct)
IL (1) IL116385A (Direct)
MA (1) MA23744A1 (Direct)
MY (1) MY131126A (Direct)
NO (1) NO316645B1 (Direct)
NZ (1) NZ297797A (Direct)
PT (1) PT799209E (Direct)
SA (1) SA95160421B1 (Direct)
TW (1) TW313568B (Direct)
WO (1) WO1996019459A1 (Direct)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
DK0897914T3 (da) 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ES2252894T3 (es) * 1998-08-10 2006-05-16 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de 2-carbamoil piridinas.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
HUP0201402A3 (en) * 1999-09-03 2003-12-29 Actelion Pharmaceuticals Ltd Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0204168A2 (hu) * 1999-12-22 2003-04-28 Actelion Pharmaceuticals Ltd. Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CN1318404C (zh) 2002-02-11 2007-05-30 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
MXPA05005793A (es) * 2002-12-02 2005-08-16 Actelion Pharmaceuticals Ltd Pirimidina-sulfamidas y su uso como antagonistas de receptor de endotelina.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2005089731A2 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2009006082A (es) 2006-12-08 2009-08-18 Lexicon Pharmaceuticals Inc Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
NZ616957A (en) 2007-02-19 2015-06-26 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
JP5555635B2 (ja) 2007-11-05 2014-07-23 ノバルティス アーゲー 高脂血症または動脈硬化症などの疾患の処置に有用なｃｅｔｐ阻害剤としての４−ベンジルアミノ−１−カルボキシアシル−ピペリジン誘導体
PT2404901E (pt) 2007-12-03 2013-08-29 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
UY32660A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados aminobutricos sustituidos como inhibidores de neprilisina
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh) 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
RU2013123793A (ru) 2010-11-24 2014-12-27 Лексикон Фармасьютикалз, Инк. Антитела, связывающиеся с notum пектинацетилэстеразой
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
JP6501775B2 (ja) 2013-07-25 2019-04-17 ノバルティス アーゲー 心不全治療用の環状ポリペプチド
AP2016009019A0 (en) 2013-07-25 2016-02-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
CN116456984A (zh) * 2020-11-05 2023-07-18 爱杜西亚药品有限公司 克拉生坦二钠盐的稳定结晶水合物
WO2023111299A1 (en) 2021-12-17 2023-06-22 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
WO2025151724A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines as modulators of atp -binding cassette transporters and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (Direct) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (Direct) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MA23744A1 (fr) 1996-07-01
ATE246681T1 (de) 2003-08-15
AU4304196A (en) 1996-07-10
HUT77884A (hu) 1998-09-28
AU701767B2 (en) 1999-02-04
EP0799209A1 (en) 1997-10-08
EP0799209B1 (en) 2003-08-06
PT799209E (pt) 2003-12-31
NO316645B1 (no) 2004-03-22
DE69531457T2 (de) 2004-06-24
HU228619B1 (en) 2013-04-29
FI972628L (fi) 1997-06-18
ES2203649T3 (es) 2004-04-16
DE69531457D1 (en) 2003-09-11
CY2495B1 (en) 2005-09-02
CA2208018A1 (en) 1996-06-27
MX9704587A (es) 1998-07-31
US6004965A (en) 1999-12-21
IL116385A (en) 2000-07-16
TW313568B (Direct) 1997-08-21
NO972538D0 (no) 1997-06-04
KR100445085B1 (ko) 2004-10-14
JPH10509182A (ja) 1998-09-08
CZ287916B6 (cs) 2001-03-14
FI972628A0 (fi) 1997-06-18
HK1001973A1 (en) 1998-07-24
MY131126A (en) 2007-07-31
CN1170407A (zh) 1998-01-14
BR9510104A (pt) 1997-11-25
CN1098254C (zh) 2003-01-08
CA2208018C (en) 2007-03-27
WO1996019459A1 (en) 1996-06-27
NO972538L (no) 1997-06-04
DK0799209T3 (da) 2003-11-24
SA95160421B1 (ar) 2006-05-01
IL116385A0 (en) 1996-03-31
CZ187497A3 (en) 1997-10-15
JP2989014B2 (ja) 1999-12-13
NZ297797A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
FI120397B (fi) Uudet sulfonamidit
FI112944B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten sulfonyyliaminopyrimidiinijohdannaisten valmistamiseksi
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
KR100478797B1 (ko) 엔도텔린 수용체 길항제로서의 4-(헤테로사이클릴설폰아미도)-6-메톡시-5-(2-메톡시페녹시)-2-페닐- 또는 -피리딜-피리미딘
WO2001017976A1 (en) Bis-sulfonamides
US7091201B2 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
CZ289920B6 (cs) Derivát sulfonamidu, způsob jeho přípravy, farmaceutický prostředek, který ho obsahuje a meziprodukt pro jeho přípravu
WO2001081335A1 (en) Pyrimidine-sulfonamides having endothelin-antagonist activity
JPH09110840A (ja) 新規なスルホニルアミノピリミジン類
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
WO2002083650A1 (en) Novel sulfonylamino-pyrimidines
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
MXPA97004587A (es) Sulfonamidas novedosas
PL185692B1 (pl) Nowe sulfonamidy, sposób ich wytwarzania oraz zawierające je preparaty farmaceutyczne
HK1001973B (en) Sulfonamides
EP1322624B1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120397

Country of ref document: FI

MA Patent expired